vs

Side-by-side financial comparison of ARDELYX, INC. (ARDX) and AST SpaceMobile, Inc. (ASTS). Click either name above to swap in a different company.

ARDELYX, INC. is the larger business by last-quarter revenue ($94.5M vs $54.3M, roughly 1.7× AST SpaceMobile, Inc.). ARDELYX, INC. runs the higher net margin — -39.8% vs -136.2%, a 96.4% gap on every dollar of revenue. On growth, AST SpaceMobile, Inc. posted the faster year-over-year revenue change (2758.2% vs 27.5%).

Ardelyx, Inc. is a commercial-stage biopharmaceutical firm developing and commercializing innovative therapies for gastrointestinal, cardiorenal and metabolic diseases with high unmet medical needs. Its lead product is approved in the US for irritable bowel syndrome with constipation, and it holds a robust pipeline of early and late-stage drug candidates.

AST SpaceMobile, Inc. is a publicly traded satellite designer and manufacturer based in Midland, Texas, United States. The company is building the SpaceMobile satellite constellation, a space-based cellular broadband network designed to connect directly to standard, unmodified smartphones. The network is intended to deliver 4G and 5G broadband coverage globally, particularly in remote and underserved regions.

ARDX vs ASTS — Head-to-Head

Bigger by revenue
ARDX
ARDX
1.7× larger
ARDX
$94.5M
$54.3M
ASTS
Growing faster (revenue YoY)
ASTS
ASTS
+2730.7% gap
ASTS
2758.2%
27.5%
ARDX
Higher net margin
ARDX
ARDX
96.4% more per $
ARDX
-39.8%
-136.2%
ASTS

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
ARDX
ARDX
ASTS
ASTS
Revenue
$94.5M
$54.3M
Net Profit
$-37.6M
$-74.0M
Gross Margin
Operating Margin
-175.0%
Net Margin
-39.8%
-136.2%
Revenue YoY
27.5%
2758.2%
Net Profit YoY
-106.3%
EPS (diluted)
$-0.15

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARDX
ARDX
ASTS
ASTS
Q1 26
$94.5M
Q4 25
$125.2M
$54.3M
Q3 25
$110.3M
$14.7M
Q2 25
$97.7M
Q1 25
$74.1M
Q4 24
$116.1M
Q3 24
$98.2M
Q2 24
$73.2M
Net Profit
ARDX
ARDX
ASTS
ASTS
Q1 26
$-37.6M
Q4 25
$-407.0K
$-74.0M
Q3 25
$-969.0K
$-122.9M
Q2 25
$-19.1M
Q1 25
$-41.1M
Q4 24
$4.6M
Q3 24
$-809.0K
Q2 24
$-16.5M
Gross Margin
ARDX
ARDX
ASTS
ASTS
Q1 26
Q4 25
91.3%
Q3 25
96.4%
Q2 25
87.3%
Q1 25
83.4%
Q4 24
84.3%
Q3 24
84.0%
Q2 24
87.1%
Operating Margin
ARDX
ARDX
ASTS
ASTS
Q1 26
Q4 25
4.1%
-175.0%
Q3 25
4.2%
-1109.0%
Q2 25
-14.7%
Q1 25
-49.0%
Q4 24
7.0%
Q3 24
2.3%
Q2 24
-18.6%
Net Margin
ARDX
ARDX
ASTS
ASTS
Q1 26
-39.8%
Q4 25
-0.3%
-136.2%
Q3 25
-0.9%
-833.7%
Q2 25
-19.5%
Q1 25
-55.5%
Q4 24
4.0%
Q3 24
-0.8%
Q2 24
-22.5%
EPS (diluted)
ARDX
ARDX
ASTS
ASTS
Q1 26
$-0.15
Q4 25
$-0.01
Q3 25
$0.00
Q2 25
$-0.08
Q1 25
$-0.17
Q4 24
$0.01
Q3 24
$0.00
Q2 24
$-0.07

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARDX
ARDX
ASTS
ASTS
Cash + ST InvestmentsLiquidity on hand
$238.1M
$4.3B
Total DebtLower is stronger
$203.5M
Stockholders' EquityBook value
$148.6M
$2.4B
Total Assets
$504.5M
$5.0B
Debt / EquityLower = less leverage
1.37×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARDX
ARDX
ASTS
ASTS
Q1 26
$238.1M
Q4 25
$68.0M
$4.3B
Q3 25
$42.7M
$2.4B
Q2 25
$90.0M
Q1 25
$30.8M
Q4 24
$64.9M
Q3 24
$47.4M
Q2 24
$41.9M
Total Debt
ARDX
ARDX
ASTS
ASTS
Q1 26
$203.5M
Q4 25
$202.8M
Q3 25
$202.1M
Q2 25
$201.4M
Q1 25
$151.3M
Q4 24
$150.9M
Q3 24
$100.7M
Q2 24
$100.2M
Stockholders' Equity
ARDX
ARDX
ASTS
ASTS
Q1 26
$148.6M
Q4 25
$166.9M
$2.4B
Q3 25
$154.3M
$1.6B
Q2 25
$139.5M
Q1 25
$145.7M
Q4 24
$173.3M
Q3 24
$158.3M
Q2 24
$147.0M
Total Assets
ARDX
ARDX
ASTS
ASTS
Q1 26
$504.5M
Q4 25
$501.6M
$5.0B
Q3 25
$486.2M
$2.6B
Q2 25
$466.8M
Q1 25
$410.2M
Q4 24
$435.8M
Q3 24
$367.9M
Q2 24
$343.5M
Debt / Equity
ARDX
ARDX
ASTS
ASTS
Q1 26
1.37×
Q4 25
1.21×
Q3 25
1.31×
Q2 25
1.44×
Q1 25
1.04×
Q4 24
0.87×
Q3 24
0.64×
Q2 24
0.68×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARDX
ARDX
ASTS
ASTS
Operating Cash FlowLast quarter
$65.0M
Free Cash FlowOCF − Capex
$-330.7M
FCF MarginFCF / Revenue
-609.0%
Capex IntensityCapex / Revenue
728.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-790.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARDX
ARDX
ASTS
ASTS
Q1 26
Q4 25
$21.0M
$65.0M
Q3 25
$365.0K
$-64.5M
Q2 25
$-25.3M
Q1 25
$-38.5M
Q4 24
$9.8M
Q3 24
$501.0K
Q2 24
$-19.4M
Free Cash Flow
ARDX
ARDX
ASTS
ASTS
Q1 26
Q4 25
$20.6M
$-330.7M
Q3 25
$209.0K
$-302.9M
Q2 25
$-26.0M
Q1 25
$-38.8M
Q4 24
$9.2M
Q3 24
$364.0K
Q2 24
$-19.5M
FCF Margin
ARDX
ARDX
ASTS
ASTS
Q1 26
Q4 25
16.4%
-609.0%
Q3 25
0.2%
-2055.0%
Q2 25
-26.6%
Q1 25
-52.3%
Q4 24
7.9%
Q3 24
0.4%
Q2 24
-26.7%
Capex Intensity
ARDX
ARDX
ASTS
ASTS
Q1 26
Q4 25
0.3%
728.7%
Q3 25
0.1%
1617.6%
Q2 25
0.7%
Q1 25
0.4%
Q4 24
0.5%
Q3 24
0.1%
Q2 24
0.2%
Cash Conversion
ARDX
ARDX
ASTS
ASTS
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
2.11×
Q3 24
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ARDX
ARDX

IBSRELA$70.1M74%
XPHOZAH$23.3M25%
Non-cash royalty revenue related to the sale of future royalties$695.0K1%
Product supply revenue$354.0K0%

ASTS
ASTS

Products$44.4M82%
Other$7.8M14%
Sat Co$2.1M4%

Related Comparisons